Views: 1,464 | Downloads:
20
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Efficacy and Tolerability of Risperidone in Ch~c .schizophrenic Thai Patients
Werapongset W 
,
Chaisirikul S ,
Churujiporn W ,
Visanuyothin T ,
Kessawai D ,
Charisilp C ,
Ratanachata N ,
Saniclzwannaku K ,
Wangdee P ,
Bunditchate A ,
Ukranand P
,
Chaisirikul S ,
Churujiporn W ,
Visanuyothin T ,
Kessawai D ,
Charisilp C ,
Ratanachata N ,
Saniclzwannaku K ,
Wangdee P ,
Bunditchate A ,
Ukranand P Risperidone is a novel serotonin-dopamine antagonist antipsychotic in a class of benzisoxazole
derivative which has been shown to be effective in reducing psychotic symptoms in
schizophrenia. The study was designed as perspective, 8-week, multicenter, open label study in
schizophrenic patients from 6 psychiatric hospitals. One hundred and twenty cases were recruited
and 105 patients completed the study. The average total PANSS score at the baseline was 90.6
(range 60-133). Patients were evaluated with quantitative rating scales for the efficacy (PANSS
score) and extrapyramidal rating scale at week 4 and 8 after starting risperidone treatment. The
titrated dose of risperidone was given to the patients with the final dose of 6 mg risperidone
throughout the study period. At week 4, the average PANSS score was significantly reduced to
73.4 (p
derivative which has been shown to be effective in reducing psychotic symptoms in
schizophrenia. The study was designed as perspective, 8-week, multicenter, open label study in
schizophrenic patients from 6 psychiatric hospitals. One hundred and twenty cases were recruited
and 105 patients completed the study. The average total PANSS score at the baseline was 90.6
(range 60-133). Patients were evaluated with quantitative rating scales for the efficacy (PANSS
score) and extrapyramidal rating scale at week 4 and 8 after starting risperidone treatment. The
titrated dose of risperidone was given to the patients with the final dose of 6 mg risperidone
throughout the study period. At week 4, the average PANSS score was significantly reduced to
73.4 (p
Download:
PDF